NASDAQ:ENVB

Enveric Biosciences Q3 2025 Earnings Results & Report

Enveric Biosciences logo
$1.44 -0.08 (-4.95%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enveric Biosciences beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$10.81 versus the -$63.00 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Enveric Biosciences EPS Results

Actual EPS
-$10.81
Consensus EPS
-$63.00
Beat/Miss
Beat by +$52.19
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 4 quarters

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Enveric Biosciences Q3 2025 Earnings FAQ

Enveric Biosciences (NASDAQ:ENVB) reported earnings of -$10.81 per share for Q3 2025, beating the consensus estimate of -$63.00. The report was announced on Friday, November 14, 2025.

Enveric Biosciences Earnings Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB) is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety.

The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines.

Enveric expanded into psychedelic-inspired drug discovery through its 2021 acquisition of MagicMed Industries. It is headquartered in Naples, Florida.

View Enveric Biosciences Profile